Global Circulating Tumor Cells (CTC) Liquid Biopsy Market is Growing with a CAGR of 25.3% in the Forecast Period of 2022 to 2029

Global Circulating Tumor Cells (CTC) Liquid Biopsy Market is growing with factors such as rising prevalence of cancer, advantages of liquid biopsy over surgical biopsy, increasing FDA approval, growing R&D activities associated with CTC liquid biopsy for the novel product launch along with government support, rising collaborations among key market players among others. The large number of market players is also propelling the demand of the market.

However, the high cost of R&D activities and shortage of skilled personnel impact the demand of the market.

Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Scenario  

According to Data Bridge Market Research, the market for global circulating tumor cells (CTC) liquid biopsy in North America has the highest market share followed by Europe and Asia-Pacific. Market leader is Guardant Health which accounts an estimated market share of approximately 12.28% in the global market. The company has gained outstanding sale by providing novel technology based epigenetics equipment.

  • In November 2021, Guardant Health announced the result of study which shows that Guardant 360 liquid biopsy test is helping in the treatment for patients with colorectal cancer. This will help the company to develop innovative tests.

Circulating Tumor Cells (CTC) Liquid Biopsy Market Trends Impacting the Market

Now the question is which other regions Guardant Health, Eurofins Genomics & FOUNDATION MEDCINE, INC. are targeting? Data Bridge Market Research has forecasted a large growth in North America circulating tumor cells (CTC) liquid biopsy market and the market leaders targeting Europe and Asia-Pacific to be their next pocket revenue for 2021.

The circulating tumor cells (CTC) liquid biopsy market is becoming more competitive with companies Guardant Health, Eurofins Genomics & FOUNDATION MEDCINE, INC. These are the top dominating companies in circulating tumor cells (CTC) liquid biopsy market and have launched novel circulating tumor cells (CTC) liquid biopsy products in the market. The data bridge market research new reports highlight the major growth factors and opportunities in the global circulating tumor cells (CTC) liquid biopsy market.

For more analysis on the global circulating tumor cells (CTC) liquid biopsy market request for a briefing with our analysts https://www.databridgemarketresearch.com/speak-to-analyst/?dbmr=global-circulating-tumor-cells-ctc-liquid-biopsy-market

Global Circulating Tumor Cells (CTC) Liquid Biopsy Market Developments

  • In August 2021, FOUNDATION MEDICINE, INC. announced that it has entered into partnership with Epic to integrate its genomic profiling with Epic’s electronic medical record system. This will help the company to support oncology practices in advanced manner.
  • In August 2021, Illumin Inc. announced that it has acquired GRAIL to accelerate patient access to multi cancer early detection test. This will help the company to increase its product portfolio.

Scope of the Circulating Tumor Cells (CTC) Liquid Biopsy Market

Global circulating tumor cells (CTC) liquid biopsy market is segmented on the basis of countries into the U.S., Canada, Mexico, Germany, France, Italy, U.K., Spain, Switzerland, Russia, Netherlands, Belgium, Ireland, Turkey, Rest of Europe, China, Japan, India, Australia, South Korea, Singapore, Thailand, Malaysia, Philippines, Indonesia, Rest of Asia-Pacific, Brazil, Argentina, Rest of South America, South Africa, Saudi Arabia, UAE, Israel, Egypt and Rest of Middle East and Africa.

  • All country based analysis of the global epigenetics diagnostic market is further analysed based on maximum granularity into further segmentation. On the basis of technology, global circulating tumor cells (CTC) liquid biopsy market is segmented into CTC detection methods, CTC enrichment methods, ex vivo positive selection, molecular (RNA)-based technologies, functional in vitro cell invasion assay, xenotransplantation methods, microchips, single spiral microchannel, negative selection and immunocytochemical technologies. On the basis of application, global circulating tumor cells (CTC) liquid biopsy market is segmented into cancer stem cell research, multiple chromosome abnormalities and others. On the basis of end user, global circulating tumor cells (CTC) liquid biopsy market is segmented into research and academic institutes, reference laboratories and hospitals and physician laboratories.

To know more about the study https://www.databridgemarketresearch.com/reports/global-circulating-tumor-cells-ctc-liquid-biopsy-market

Key Pointers Covered in Circulating Tumor Cells (CTC) Liquid Biopsy Market Industry Trends and Forecast to 2029

  • Market Size
  • Top to Bottom Market Analysis
  • Recent Developments for Market Competitors
  • Recent Market Value for Different Countries
  • Market value and over view of circulating tumor cells (CTC) liquid biopsy market
  • Company profiling of top eight players of circulating tumor cells (CTC) liquid biopsy market

Key Market Competitors Covered in the Report

  • Eurofins Genomics ( a subsidiary of Eurofins Scientific)
  • MDx Health
  • Guardant Health
  • IMMUCOR
  • Thermo Fisher Scientific, Inc.
  • Menarini Silicon Biosystems
  • QIAGEN
  • Exact Sciences Corporation
  • Myriad Genetics, Inc.
  • LungLife AI, Inc.
  • Bio-Rad Laboratories, Inc.
  • Illumina, Inc.
  • Natera Inc.,
  • ExoDx ( a subsidiary of Bio-Techne Corporation)
  • Biocept, Inc.
  • F. Hoffman-La Roche Ltd.
  • FOUNDATION MEDICINE, INC.
  • Lucence Health, Inc.
  • Inivata Ltd
  • Biolidics Limited
  • Vortex Biosciences

Research Methodology: Global Circulating Tumor Cells (CTC) Liquid Biopsy Market

Data collection and base year analysis is done using data collection modules with large sample sizes. The market data is analyzed and forecasted using market statistical and coherent models. Also market share analysis and key trend analysis are the major success factors in the market report. To know more please request an analyst call or can drop down your enquiry.

The key research methodology used by DBMR research team is data triangulation which involves data mining, analysis of the impact of data variables on the market, and primary (industry expert) validation. Apart from this, data models include vendor positioning grid, market time line analysis, market overview and guide, company positioning grid, company market share analysis, standards of measurement, top to bottom analysis and vendor share analysis. To know more about the research methodology,

drop in an inquiry to speak to our industry experts https://www.databridgemarketresearch.com/toc/?dbmr=global-circulating-tumor-cells-ctc-liquid-biopsy-market

Primary Respondents

  • Demand Side: Manufacturer, Geneticists, Healthcare Industry, Scientists, Research Laboratories
  • Supply Side: Product Managers, Marketing Managers, C-Level Executives, Distributors, Market Intelligence, and Regulatory Affairs Managers among others.

Related Reports

Browse in Healthcare Category Related Reports@ https://www.databridgemarketresearch.com/report-category/healthcare/